Table 1. Pretreatment Characteristics of Patients Included in the Analyses.*.
| Characteristic | Patients with Negative PET Findings | Patients with Positive PET Findings Who Received BEACOPP (N = 172) | All Eligible Patients (N = 1203) | |
|---|---|---|---|---|
| ABVD (N = 470) | AVD (N = 465) | |||
| Age at registration — yr | ||||
| Median | 32 | 33 | 32 | 33 |
| Range | 18–79 | 18–76 | 18–70 | 18–79 |
| Age — no. (%) | ||||
| 18–24 yr | 121 (25.7) | 117 (25.2) | 47 (27.3) | 299 (24.9) |
| 25–44 yr | 231 (49.1) | 223 (48.0) | 75 (43.6) | 576 (47.9) |
| 45–59 yr | 80 (17.0) | 81 (17.4) | 32 (18.6) | 213 (17.7) |
| ≥60 yr | 38 (8.1) | 44 (9.5) | 18 (10.5) | 115 (9.6) |
| Male sex — no. (%) | 261 (55.5) | 252 (54.2) | 92 (53.5) | 656 (54.5) |
| ECOG performance status — no. (%)† | ||||
| 0 | 340 (72.3) | 354 (76.1) | 123 (71.5) | 889 (73.9) |
| 1 | 113 (24.0) | 96 (20.6) | 40 (23.3) | 271 (22.5) |
| 2 | 11 (2.3) | 9 (1.9) | 6 (3.5) | 28 (2.3) |
| 3 | 6 (1.3) | 6 (1.3) | 2 (1.2) | 14 (1.2) |
| Missing | 0 | 0 | 1 (0.6) | 1 (0.1) |
| Ann Arbor stage — no. (%) | ||||
| II | 195 (41.5) | 197 (42.4) | 73 (42.4) | 500 (41.6) |
| III | 157 (33.4) | 140 (30.1) | 34 (19.8) | 363 (30.2) |
| IV | 118 (25.1) | 128 (27.5) | 65 (37.8) | 340 (28.3) |
| B symptoms — no. (%)‡ | 287 (61.1) | 277 (59.6) | 121 (70.3) | 738 (61.3) |
| Bulky disease — no. (%) | 133 (28.3) | 150 (32.3) | 79 (45.9) | 386 (32.1) |
| International prognostic score — no. (%)§ | ||||
| 0 or 1 | 170 (36.2) | 172 (37.0) | 34 (19.8) | 404 (33.6) |
| 2 or 3 | 219 (46.6) | 224 (48.2) | 84 (48.8) | 579 (48.1) |
| ≥4 | 75 (16.0) | 67 (14.4) | 52 (30.2) | 209 (17.4) |
| Missing | 6 (1.3) | 2 (0.4) | 2 (1.2) | 11 (0.9) |
Positron-emission tomographic (PET) findings on the interim PET–computed tomographic (PET-CT) scan were scored with the use of a 5-point scale, according to the level of any residual uptake of 18F-fluorodeoxyglucose at involved sites on baseline PET and with higher scores indicating greater uptake. A score of 1, 2, or 3 was regarded as indicating negative findings, and a score of 4 or 5 was regarded as indicating positive findings. ABVD denotes doxorubicin, bleomycin, vinblastine, and dacarbazine, AVD doxorubicin, vinblastine, and dacarbazine, and BEACOPP bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone.
Values for the Eastern Cooperative Oncology Group (ECOG) performance status range from 0 to 5, with higher scores indicating greater disability.
Systemic B symptoms include weight loss, night sweats, and fever.
The international prognostic score ranges from 0 to 7, with higher scores indicating increased risk.